The Scientist

» DNA methylation, ecology and disease/medicine

Most Recent

image: Tumor Snipers

Tumor Snipers

By | November 1, 2012

After two headline successes, companies rush to develop “smart bomb” cancer drugs.

0 Comments

image: A Celebrated Symposium

A Celebrated Symposium

By | November 1, 2012

After two headline successes, companies rush to develop “smart bomb” cancer drugs.

0 Comments

image: Long and Rocky Roads

Long and Rocky Roads

By | November 1, 2012

After two headline successes, companies rush to develop “smart bomb” cancer drugs.

0 Comments

image: Metabolomics Sheds Light on TB Drug

Metabolomics Sheds Light on TB Drug

By | November 1, 2012

After two headline successes, companies rush to develop “smart bomb” cancer drugs.

1 Comment

image: A Window into Cancer

A Window into Cancer

By | October 31, 2012

After two headline successes, companies rush to develop “smart bomb” cancer drugs.

2 Comments

image: Opinion: Fishy Deaths

Opinion: Fishy Deaths

By | October 29, 2012

After two headline successes, companies rush to develop “smart bomb” cancer drugs.

1 Comment

image: Viruses Affect Cell Reprogramming

Viruses Affect Cell Reprogramming

By | October 25, 2012

After two headline successes, companies rush to develop “smart bomb” cancer drugs.

6 Comments

image: Eggs Trade Genes

Eggs Trade Genes

By | October 24, 2012

After two headline successes, companies rush to develop “smart bomb” cancer drugs.

0 Comments

image: Robot Mends Hearts in Britain

Robot Mends Hearts in Britain

By | October 24, 2012

After two headline successes, companies rush to develop “smart bomb” cancer drugs.

0 Comments

image: Cranking Up Biosecurity

Cranking Up Biosecurity

By | October 24, 2012

After two headline successes, companies rush to develop “smart bomb” cancer drugs.

0 Comments

Popular Now

  1. How Plants Evolved Different Ways to Make Caffeine
  2. Thomson Reuters Predicts Nobelists
    The Nutshell Thomson Reuters Predicts Nobelists

    According to citation statistics, researchers behind programmed cell death pathways and CRISPR/Cas9 are among those in line for Nobel Prizes this year.

  3. Monsanto Buys Rights to CRISPR
    The Nutshell Monsanto Buys Rights to CRISPR

    The US agribusiness secures a global, nonexclusive licensing agreement from the Broad Institute to use the gene-editing technology for agricultural applications.

  4. Reviewing Results-Free Manuscripts
    The Nutshell Reviewing Results-Free Manuscripts

    An open-access journal is trialing a peer-review process in which reviewers do not have access to the results or discussion sections of submitted papers.

RayBiotech